Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
Tamoxifen is a well-known hormone tablet used to lower the chance of breast cancer returning after surgery. Usually, doctors prescribe it for five years. However, researchers want to know if continuing to take tamoxifen for another five years gives even better long-term protection. This trial compares women who stop taking tamoxifen after their initial treatment with women who keep taking it for five more years. Researchers will carefully weigh the benefits of stopping cancer from returning against the potential side effects of taking the medication for longer. Taking part is completely voluntary. If you join, you will be randomly chosen to either continue taking daily tamoxifen tablets or to stop taking them as originally planned. Your regular hospital care and routine check-ups will continue as normal throughout the study.
At a glance
What is this study about?
Many breast cancers rely on the hormone oestrogen to grow. Tamoxifen is a daily tablet that blocks oestrogen from reaching cancer cells, which helps stop any remaining cells from growing or spreading. For a long time, the standard approach has been to take tamoxifen for five years following breast cancer surgery.
Doctors now want to answer an important question: does extending this treatment to ten years give women better protection, or do the extra years simply cause unnecessary side effects? Because doctors are currently unsure which option is best, this clinical trial was set up to find a clear, reliable answer.
By comparing women who carry on with tamoxifen for another five years against those who stop, the study will show whether longer treatment saves more lives and prevents more recurrences. The findings from this research will help shape future breast cancer treatment guidelines across the NHS and worldwide.
Key takeaways
- Tests whether taking tamoxifen for 10 years is better than the usual 5 years.
- Open to women who have had breast surgery and have already taken tamoxifen for at least two years.
- A computer randomly decides whether you continue taking tamoxifen or stop.
- Involves your usual hospital check-ups with no demanding extra visits.
- You can leave the study at any time without it affecting your NHS care.
Who may be eligible?
This trial is designed for women who have had surgery to completely remove their breast cancer and have already taken tamoxifen for at least two years (though five years is preferred).
To be eligible, you must currently be free of cancer, with no signs that the disease has returned. You and your doctor should also feel uncertain about whether continuing tamoxifen is the right choice for you, meaning there is no clear medical reason why you definitely should or should not stay on the medication.
Where possible, doctors will check if your breast cancer was sensitive to hormones (known as ER status). Women of any age can take part as long as they meet these health criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a woman who has had surgery to remove breast cancer.
- I have taken tamoxifen for at least 2 years (preferably 5 years).
- I am currently free of cancer with no signs of it returning.
- My doctor is unsure whether continuing tamoxifen would benefit me.
- I am willing to either continue or stop taking tamoxifen based on random selection.
What does participation involve?
If you decide to join the study, you will be placed into one of two groups by chance (randomisation). One group will stop taking tamoxifen, which is standard practice. The other group will carry on taking one tamoxifen tablet every day for an additional five years.
Neither you nor your doctor can choose your group, ensuring the study results are fair and reliable. You will not need extra hospital visits beyond your normal cancer follow-up care. During your routine appointments, your doctor will check your overall health, monitor for any signs of cancer returning, and ask about any side effects you might be having.
You will be followed up for several years so researchers can track your long-term health. Taking part will not change the standard of care and support you receive from your clinical team.
Potential risks and benefits
Locations (1)
- Cancer Research UK Clinical Trials Unit (CRCTU)City onlyBirmingham, England
Common questions
What is tamoxifen?
Tamoxifen is a daily hormone therapy tablet that stops oestrogen from helping breast cancer cells grow.
Can I choose whether to stay on tamoxifen or stop?
No. A computer puts you into a group at random so that researchers can make a fair comparison between the two choices.
Does being invited mean my cancer has returned?
No. You can only join this trial if there is no sign of your cancer coming back.
What happens if I get severe side effects?
You should tell your doctor straight away. If needed, you can stop taking the medication at any point.
Will taking part cost me anything?
No. The trial is run through your regular NHS hospital care, and you will not have to pay for the study treatment.
How to find out more
Claire Gaunt
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.